Member Announcements - 2008
December 16, 2008December 15, 2008
December 15, 2008
December 10, 2008
December 4, 2008
December 3, 2008
VICTORIA - The Province is seeking three members of the public to provide input on the medications provided to British Columbians under the PharmaCare drug insurance program, announced Health Services Minister George Abbott today.
BELLEVILLE, ON, Oct. 27 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that Econiche(TM), the world's first vaccine designed to reduce the
shedding by cattle of Escherichia coli (E. coli) O157:H7, has received full
licensing approval from the Canadian Food Inspection Agency (CFIA). Econiche
is now available for unrestricted use by Canadian cattle producers and their
veterinarians.
November 18, 2008
VANCOUVER - Farris, Vaughan, Wills & Murphy LLP (Farris), one of Canada’s leading law firms, today welcomes The Honourable David Emerson, P.C., formerly Canada’s Minister of Foreign Affairs, to the firm as Senior Advisor.
November 18, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to report that iCo-009, the company’s oral Amphotericin B program, has been accepted for a poster presentation at the American Association of Pharmaceutical Scientist (AAPS) Meeting in Atlanta, GA.
Vancouver, B.C. - EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company”) today announced that it has completed its final modifications to its continuous commercial-scale nutraREV food dehydration equipment and has started the final testing phase at the blueberry processing facility of CAL-SAN Enterprises Ltd. in Richmond, B.C.
November 7, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to report that oral administration of iCo-009, iCo’s oral formulation of Amphotericin B, displays a dramatic knock-down of a parasitic infection that causes Visceral Leishmaniasis (VL). The studies were undertaken at an independent research laboratory in the United States with significant experience with VL animal models.
MISSISSAUGA, ON. (Nov. 1, 2008) – Amgen Canada today announced that applications for the Amgen Award for Science Teaching Excellence (AASTE) are now open and is encouraging teachers in BC, Alberta, Ontario and Quebec to apply. The AASTE is designed to recognize and honour teachers who demonstrate exemplary science teaching and who achieve demonstrated results in student learning at the K-12 level in Canada.
November 3, 2008
October 31, 2008
VANCOUVER, B.C., CANADA – Oct. 31, 2008 – Biolux Research Ltd. is pleased to announce today that it has launched the OsseoPulseTM Bone Regeneration System in Canada. The product is now available for sale through Citagenix Inc., our exclusive distribution partner. The product has been approved by Health Canada as a class II medical device, and received a medical device license earlier in 2008. Production quality has been proven, sales training has taken place, and product has been shipped to Citagenix to begin marketing and sales.
October 31, 2008
October 30, 2008
BURNABY, BC, Oct. 30, 2008 - Welichem Biotech Inc. (the "Company") (TSX-V: WBI) is pleased to announce the positive results from its Phase IIa clinical trial of its drug candidate, WBI-1001, a new, non-steroid, topical cream treatment for atopic dermatitis (AD). In the trial, two concentrations (0.5% and 1.0%) of WBI-1001 were tested against the placebo. Both WBI-1001 cream concentrations were superior
to placebo in deceasing AD and showed an excellent safety profile. Welichem plans to conduct further clinical trials for WBI-1001 in 2009. "We are very pleased to be able to present such positive results from the Company's clinical trial on atopic dermatitis," says Dr. Genhui Chen, Chief Executive Officer of Welichem." AD is a major unmet medical indication, and these positive results are of significance for our overall strategy of developing WBI-1001 for the treatment of this disease and additional conditions."
October 28, 2008
Genome British Columbia has announced the results of the first Science Opportunities Fund competition in which nine awards have been made to researchers in the Province with a total approved budget of $2.3 million. The nine teams of researchers located in Vancouver, the Okanagan and on Vancouver Island are launching peer-reviewed, short-term research projects the results of which will have impacts on important sectors of BC’s economy and environment.
October 22, 2008
October 16, 2008
October 14, 2008
October 9, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce a series of positive experiments investigating the systemic bioavailability of amphotericin B following oral administration. iCo-009 is iCo’s oral formulation of Amphotericin B, a broad spectrum antifungal drug which currently can only be delivered by intravenous (IV) infusion. Results indicate that oral administration of iCo-009 results in blood levels that are comparable to a known IV Amphotericin B product currently on the market.
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO), a reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications, is pleased to announce that iCo has been selected as one of Canada's Top 10™ Competition winners. Top 10™ winners are chosen by an independent expert panel of Canadian and U.S. venture capitalists. The panel can be viewed at
http://www.topcanadiancompanies.ca/jury/ls_jury.html.
VANCOUVER, Sept. 30 - Lignol Energy Corporation (TSX-V: LEC) ("Lignol"
or "the Company"), a leading technology company in the lignocellulosic
biorefining sector, today announced that it has signed a Memorandum of
Understanding (the "MOU") with Weyerhaeuser Company ("Weyerhaeuser")
(NYSE: WY) to explore the development of commercial applications of
biochemical outputs from Lignol's proprietary biorefining technology.
September 29, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO), a reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications, is pleased to announce that iCo will present at the BioContact Québec 2008 conference.
EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") today announced that it has received positive results from a second shelf-life study of dehydrated rotavirus vaccine conducted by its collaboration partner Aridis Pharmaceuticals, LLC (“ Aridis”) of San Jose, California using EnWave’s bioREV technology.
September 22, 2008
Vancouver, Canada, September 22, 2008: Contract research organizations (CROs) are a mainstay of clinical development. When you outsource clinical development to CROs, you are taking one of the most expensive processes your company performs – a process upon which the future success of your company depends – and giving it to someone else to manage. As a result, problems selecting and managing CROs can be expensive and put the future success of your company at risk.
September 22, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to report interim results from iCo’s ongoing iCo-007 clinical trial. The phase I, open-label, dose escalation study is evaluating the safety, tolerability, and pharmacokinetics of a single intravitreal injection of iCo-007 in patients with diffuse diabetic macular edema (DME).
EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") today announced that it has made a major innovation in its Radiant Energy Vacuum (“REV”) pharmaceutical dehydration technology to allow for a significant reduction in the moisture content of dried vaccine products.
Vancouver, B.C. - EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") has successfully installed a batch unit of its proprietary food dehydration technology, nutraREV, into a Saskatchewan berry processing facility to test the machine’s ability to dehydrate Saskatoon berries into a commercially saleable product.
July 9, 2008
Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") today announced that it has achieved an important milestone by producing a saleable dried blueberry product using its continuous nutraREV dehydration equipment.
July 8, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce the addition of Mr. Noel Hall and Dr. Christian Fibiger to iCo’s Board of Directors. Mr. Hall was most recently co–founder, President and Director of Aspreva Pharmaceuticals Corporation, which was acquired by the Galenica Group for $915M (USD) in January 2008. Dr. Fibiger was most recently Vice President and Global Head of Neuroscience for Amgen Inc. and, during his academic career, was one of the top 100 most cited scientists in neuroscience.
July 8, 2008
Welichem Biotech Inc. (the "Company") (TSX-V: WBI) announces today the successful completion of and the results from a randomized, double-blinded Phase I clinical trial done in Montreal, Canada, which evaluated topically applied WBI-1001 in 36 psoriasis patients.
July 7, 2008
July 7, 2008
June 26, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to provide further preclinical results supporting the accelerated development of iCo-009, the company’s oral reformulation of Amphotericin B (Amp B). Amp B is a generic drug that has been in use for approximately 50 years, however its use is limited as it is currently administered intravenously and has significant infusion related side effects and kidney toxicity.
Vancouver, Canada, June 23, 2008: Many clinical-trial professionals sense they are not getting the best value out of contract research organizations (CROs), citing ambiguity in pricing, poor communication, waning commitment to projects and lack of strategic fit.
June 17, 2008
Forbes Medi-Tech Inc. announced today that the Company has demonstrated compliance with Nasdaq's Minimum Bid Price Requirement, as evidenced by a closing bid price of $1.00 or more for a minimum of ten consecutive trading days.
June 9, 2008
The Company annouced today that the Nasdaq Hearings Panel has granted the Company an extension through June 30, 2008, to demonstrate compliance with the Minimum Bid Price Requirement for continued listing on the Nasdaq Stock Market.
June 9, 2008
Vancouver, BC Pyng Medical Corp. (PYT: TSX .V) today announced it has completed the acquisition of the trauma assets of California-based Bio Cybernetics International (BCI) (dba “Cybertech Medical”, www.cybertechmedical.com), including the market leading Trauma Pelvic Orthotic Device (TPOD®), Mechanical Advantage Tourniquet (MAT®), and Cricothyrotomy Kit (CRIC™).
June 6, 2008
[Munich, Germany and Vancouver, Canada; June, 2008] Harrison
Clinical Research (HCR) and ASKA Research (ASKA) are proud to announce
that they have agreed on a formal strategic alliance to expand the
global reach of both companies and to better serve their clients in all
aspects of global drug and medical device development, education
services, and clinical trial management.
June 5, 2008
Pacgen Biopharmaceuticals Corporation ("Pacgen") (TSX VENTURE: PGA) today announced positive results from its Phase IIb dose-ranging trial of PAC-113, a novel anti-fungal drug candidate.
June 3, 2008
June 3, 2008
Vancouver, B.C. - EnWave Corporation (TSX-V: ENW) (“EnWave”, or the "Company"), has engaged the services of AXINO AG (“AXINO”) of Stuttgart, Germany to undertake investor relations activities for the Company in Germany and other European countries. AXINO is an investor relations agency providing a wide range of services to companies to help broaden investor exposure, develop a shareholder following and identify financing opportunities in the European financial markets.
June 2, 2008
VANCOUVER, British Columbia, Canada – June 2, 2008 – OncoGenex Technologies Inc. announced today that the Company’s lead cancer drug candidate, OGX-011, continues to show better than expected survival results in patients with hormone refractory prostate cancer (HRPC) when compared to published results. OGX-011, also referred to as custirsen sodium, is a second-generation antisense oligonucleotide designed to facilitate tumor cell death induced by chemotherapy by decreasing production of clusterin, a cell survival protein linked to treatment resistance. Preliminary analyses have shown that low-average levels of serum clusterin were predictive of the survival benefit. Additionally, patients treated with second-line chemotherapy plus OGX-011 experienced a reduction in pain that was durable as well as a decline in PSA. These data were presented by Dr. Fred Saad, Professor of Surgery/Urology at the University of Montreal, on June 1 at the 2008 Annual Meeting of the American Society of Clinical Oncology. OncoGenex and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) are collaborating on development of OGX-011.
June 2, 2008
June 2, 2008
-$10.0 Million Private Placement with Alnylam Pharmaceuticals and Roche Completed-
Vancouver, B.C. - EnWave Corporation (TSX-V: ENW) (“EnWave”, or the "Company"), wishes to announce the closing of the non-brokered private placement originally announced on May 06, 2008. The placement has raised $1,065,150 by issuing 3,550,501 units at a price of $0.30 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles its holder to purchase one common share of the Company at a price of $0.45 per share until May 30, 2010.
May 28, 2008
BOTHELL, Washington and VANCOUVER, British Columbia – May 28, 2008 – Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) and OncoGenex Technologies Inc., a privately held biopharmaceutical development company, today jointly announced the signing of a definitive agreement to merge the two companies. The combined company will operate as OncoGenex Pharmaceuticals, Inc. Scott Cormack, OncoGenex’ current President and Chief Executive Officer will continue as President and CEO of the company. As a result of the merger, the combined company will have a strong oncology pipeline addressing distinct unmet needs in the treatment of cancer, including three candidates in various stages of clinical development. Its lead candidate, OGX-011, is being evaluated in five Phase 2 clinical trials, each of which has completed patient enrollment. Interim study results have previously been presented for each of the five clinical trials.
May 22, 2008
The Company today announced that Greg Anderson was appointed to the Company’s Board of Directors and Dr. Joe Dunne was named as Chairman. As approved at the Company’s Annual General Meeting (“AGM”), the current composition of Forbes’ Board is now fixed at four Directors and includes Dr. Joe Dunne, Nitin Kaushal, Greg Anderson, and Charles Butt
May 20, 2008
May 15, 2008
The Company today announced a plan to focus exclusively on its revenue-generating nutraceutical business, which includes functional foods and dietary supplements, and cease all in-house drug development activities.
May 14, 2008
The Company today announced its results for the first quarter 2008 ended March 31, 2008.
May 14, 2008
Vancouver, B.C. - EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") has announced the lease of a batch unit of its proprietary food dehydration technology, nutraREV, to a Saskatoon, Saskatchewan-based berry processing company, Riverbend Plantation, Inc. The company will test the feasibility of using nutraREV to dehydrate Saskatoon berries into a commercially saleable product for the North American and European markets.
May 12, 2008
The Company today announced that, as part of its continuing reorganization plan, it has completed the previously announced transaction with a private investor (the “Investor”) to reorganize Forbes Medi-Tech Operations Inc. (“FMTO”), a wholly owned subsidiary of Forbes.
May 7, 2008
Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave”, or the "Company"), further to its May 6, 2008 press release, wishes to announce that it has changed some of the terms of the non-brokered private placement. The offer will be for up to 3,000,000 units at a price of $0.30 per unit. Each unit will now consist of one common share and one whole share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of $0.45 per share for a period of two years from the time of issuance of the units. All of the other terms of the placement remain unchanged.
May 6, 2008
Vancouver, B.C.-EnWave Corporation (TSX-V: ENW) (“EnWave”, or the "Company") wishes to announce that it has agreed to a non-brokered private placement of up to 2,750,000 units at a price of $0.30 per unit. Each unit will consist of one common share and one half share purchase warrant. Each whole warrant will entitle the holder to purchase one common share at an exercise price of $0.45 per share for a period of two years from the time of issuance of the units. The proceeds of up to $825,000 will be used for the ongoing development of EnWave's Radiant Energy Vacuum (bioREV, nutraREV, and powderREV) technologies, working capital and for general corporate purposes.
May 2, 2008
May 1, 2008
May 1, 2008
Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave” or the "Company") is pleased to report that it has received positive results from the Company’s first room temperature shelf-life study of dehydrated rotavirus vaccine conducted by its collaboration partner Aridis Pharmaceuticals, LLC (“Aridis”) of San Jose, California. The Company believes it is now one step closer to developing a new industry standard technology for dehydrating vaccines and antibodies.
April 29, 2008
Neuromed Pharmaceuticals, a biopharmaceutical company developing new and
improved chronic pain drugs, today announced the promotion of Sean
Cunliffe to Chief Commercial Officer.
April 24, 2008
The Company today announced it has extended its supply and licensing contract with Pharmavite LLC until mid 2009 for the continued sale of Reducol TM, the branded cholesterol lowering ingredient in one of Pharmavite's leading line of dietary supplements, Nature Made® CholestOff® and CholestOff® Complete.
April 21, 2008
Vancouver, B.C.- EnWave Corporation (TSX-V:ENW) (“EnWave” or the “Company”) is pleased to provide a corporate update to shareholders regarding the development and testing of its Radiant Energy Vacuum (REV) technology in the medical and food sectors.
April 17, 2008
April 15, 2008
Vancouver, Canada, April 15, 2008 – As BC life-science companies continue to commercialize innovative technologies, many firms have a growing need to analyze and communicate complex business issues to a variety of stakeholders, including investors, partners and senior management.
April 1, 2008
March 31, 2008
The Company today announced its financial results for the year ended December 31, 2007 versus the year ended December 31, 2006. All amounts are in Canadian dollars unless otherwise noted.
March 20, 2008
The Company today announced that, as part of its continuing reorgainztion plan, it has entered into an agreement with a private investor (the "Investor") to reorganize Forbes Medi-Tech Operations Inc. ("FMTO"), a wholly-owned subsidiary of Forbes.
March 19, 2008
The Company today announced that it has entered into collaboration wiht Max food ingredients GmbH, a member of the Uplegger food company GmbH group.
March 17, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that iCo-009 has been highlighted in a leading drug delivery journal, Advanced Drug Delivery Reviews. The paper discusses the development of a novel oral Amphotericin B (AmpB) formulation (“iCo-009”) with significant antifungal activity, minimal kidney toxicity, and enhanced oral absorption of AmpB.
March 11, 2008
Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave” or the “Company”) today announced that it has successfully applied its Radiant Energy Vacuum (REV) technology to dehydrate probiotics and enzymes used in the food and fine biochemical industries.
March 10, 2008
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to provide a clinical update on iCo-008, a human monoclonal antibody targeting eotaxin-1. iCo licensed iCo-008 from MedImmune of Cambridge, UK (formerly Cambridge Antibody Technology). iCo-008 has been in 126 patients in Phase I and II clinical trials.
March 10, 2008
Laborie Medical Technologies Receives FDA 510(k) Clearance for Tetra™ Bladder Monitor System
FDA Approval Paves the Way for Commercial Launch of Urodynamix’s NIRS Technology
VANCOUVER, British Columbia, March 10, 2008 - Urodynamix Technologies Ltd. (TSX-V:URO) today announced that its worldwide distribution partner, Laborie Medical Technologies Inc. (Laborie) has obtained 510(k) clearance from the U.S. Food and Drug Administration to market their urodynamic equipment with the Tetra™ Bladder Monitor System for non-invasive bladder testing.
March 10, 2008
The Company today announced that Fiave of Italy, one of the country’s premium dairy producers, has launched a yogurt drink containing Forbes’ cholesterol-lowering ingredient, Reducol™. The launch marks the first brand name product launch in Europe featuring Reducol™.
March 10, 2008
March 6, 2008
Vancouver, B.C.- EnWave Corporation (TSX-V: ENW) (“EnWave” or the "Company") today reported that Aridis Pharmaceuticals, LLC (“Aridis”) of San Jose, California has completed its first testing stage of the bioREV technology for use as a vaccine and antibody dehydration method.
March 5, 2008
VANCOUVER, British Columbia, March 3, 2008 - Urodynamix Technologies Ltd. (TSX-V:URO) today announced that it has entered into a collaborative agreement for the further study of its NIRS technology that could significantly improve the treatment of symptomatic benign prostatic hyperplasia, or BPH (enlarged prostate). Urodynamix has entered into an agreement to evaluate a device incorporating its NIRS sensors with existing transurethral microwave thermotherapy (TUMT) devices for the minimally invasive treatment of BPH
March 3, 2008
The Company today announced that its common shares are now trading on NASDAQ and the TSX on a post-exchange basis. Initially, the trading symbol for Forbes’ shares trading on NASDAQ will be "FMTID", - an interim symbol to denote the post-exchange status. The trading symbol “FMI” for Forbes’ shares trading on the TSX remains unchanged.
March 2, 2008
February 28, 2008
February 28, 2008 - Vancouver, B.C. - EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") today announced that after a successful test period at their Vancouver laboratory, the Company’s first continuous unit using its proprietary food dehydration technology has been installed in a commercial food processing facility in Richmond, B.C. to test large-scale production capabilities.
February 27, 2008
February 26, 2008
The Company today announced that its Board of Directors has set the share exchange ratio for the Company's corporate reorganization, which is to proceed by way of a plan of arangement (the "Arrangement"), at eight existing common shares of Forbes for one new common share.
February 26, 2008
February 20, 2008
February 15, 2008
February 15, 2008
February 14, 2008
The Company today announced that securityholders have approved the Company’s corporate reorganization. For resolutions one and two, ‘Reduction in Stated Capital’ and ‘Name Change’ respectively, over 88% of votes cast were in favor of the resolutions. For resolution three, the ‘Plan of Arrangement’, over 82% of votes cast were in favor. Prior to the meeting, the plan of arrangement was amended to broaden the range of the exchange ratio for Forbes Medi-Tech shares to a range of two to eight Forbes shares for each Newco share. The exchange ratio was adjusted in light of recent market prices, and to provide flexibility to the Board of Directors in an effort to help regain compliance with Nasdaq’s minimum US$1 bid requirement. The actual exchange ratio will be announced as soon as it is set by the Board and will affect share, option and warrant holders equally.
February 8, 2008
February 7, 2008
February 6, 2008
January 31, 2008
The Company announced today that Institutional Shareholder Services Inc. (ISS) has formally recommended that their clients holding shares in Forbes Medi-Tech vote "FOR" the proposed corporate reorganization. ISS, one of the world's leading providers of corporate governance and proxy voting solutions, conducted an independent and comprehensive analysis of Forbes’ proposed corporate reorganization and its impact on shareholders.